Literature DB >> 34120255

Functional outcomes rather than complications predict poor health-related quality of life at 6 months after robot-assisted radical prostatectomy.

Marinus J Hagens1,2,3, H Veerman4,5,6, K M de Ligt7, C N Tillier4, P J van Leeuwen4,6, R J A van Moorselaar5,6, H G van der Poel4,6.   

Abstract

The objective is to evaluate the effect of robot-assisted radical prostatectomy (RARP)-related postoperative complications on the 6-month postoperative health-related quality of life (HRQoL). A total of 1008 patients underwent a RARP with or without pelvic lymph node dissection (PLND) between 2012 and 2020 and were invited to complete questionnaires about HRQoL and functional outcomes (urinary incontinence (UI), erectile dysfunction (ED) and urinary complaints (UC)) before and 6 months after RARP. Patient characteristics and postoperative complications up to 90 days after surgery were prospectively recorded. Associations between complications and HRQoL/functional outcomes were assessed by multivariate linear regression analyses. In total, 528 patients (52.4%) were included in the analyses. Complications occurred in 165/528 (31.3%) patients, of which 30/165 (18.2%) had a Clavien-Dindo ≥ III complication. In multivariate regression analyses, postoperative complications were not significantly associated with postoperative HRQoL, UI and ED (p = 0.73, p = 0.72 and p = 0.95, respectively), but were significantly associated with a minor increase in UC (β = 1.7, p < 0.001). More specifically, infectious and urological complications were significantly associated with an increase in UC (β = 1.9, p < 0.001 and β = 0.9, p = 0.004, respectively). The presence of UTI, in particular, was significantly associated with this minor increase (β = 1.5, p = 0.002). Functional outcomes were all significantly associated with the HRQoL at 6 months postoperatively. No significant associations were found between postoperative complications and HRQoL at 6 months after RARP. However, worse functional outcomes were associated with a worse HRQoL at 6 months postoperatively. In addition, postoperative infectious and urological complications were significantly associated with a minor increase in UC.
© 2021. The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.

Entities:  

Keywords:  Erectile dysfunction (ED); Health-related quality of life (HRQoL); Postoperative complications; Prostate cancer; Robot-assisted laparoscopic radical prostatectomy (RARP); Urinary complaints (UC); Urinary incontinence (UI)

Mesh:

Year:  2021        PMID: 34120255     DOI: 10.1007/s11701-021-01266-9

Source DB:  PubMed          Journal:  J Robot Surg        ISSN: 1863-2483


  23 in total

1.  Body mass index is an independent predictor of Clavien-Dindo grade 3 complications in patients undergoing robot assisted radical prostatectomy with extensive pelvic lymph node dissection.

Authors:  Antonio Benito Porcaro; Marco Sebben; Alessandro Tafuri; Nicolò de Luyk; Paolo Corsi; Tania Processali; Marco Pirozzi; Riccardo Rizzetto; Nelia Amigoni; Daniele Mattevi; Maria A Cerruto; Matteo Brunelli; Giovanni Novella; Vincenzo De Marco; Filippo Migliorini; Walter Artibani
Journal:  J Robot Surg       Date:  2018-05-08

2.  Exploring the Optimal Erectile Function Domain Score Cutoff That Defines Sexual Satisfaction After Radical Prostatectomy.

Authors:  Jean E Terrier; John P Mulhall; Christian J Nelson
Journal:  J Sex Med       Date:  2017-06       Impact factor: 3.802

3.  Surgical and postoperative factors affecting length of hospital stay after radical prostatectomy.

Authors:  T A Gardner; E A Bissonette; G R Petroni; R McClain; M H Sokoloff; D Theodorescu
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

4.  Analysis of Quality of Life Subjective Perception by Patients Treated for Prostate Cancer with the EORTC QLQ-C30 Questionnaire and QLQ-PR25 Module.

Authors:  Marta Dąbrowska-Bender; Robert Słoniewski; Urszula Religioni; Grzegorz Juszczyk; Anna Słoniewska; Anna Staniszewska
Journal:  J Cancer Educ       Date:  2017-09       Impact factor: 2.037

5.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.

Authors:  N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes
Journal:  J Natl Cancer Inst       Date:  1993-03-03       Impact factor: 13.506

6.  A comparative analysis of complications after robot-assisted radical prostatectomy for men aged ≤69 and ≥70 years.

Authors:  Kara N Babaian; Douglas Skarecky; Michael A Liss; Kathryn Osann; Achim Lusch; Thomas E Ahlering
Journal:  J Endourol       Date:  2014-12       Impact factor: 2.942

7.  Is age an independent risk factor for medical complications following minimally invasive radical prostatectomy? An evaluation of contemporary American College of Surgeons National Surgical Quality Improvement (ACS-NSQIP) data.

Authors:  Lawrence M Dagrosa; Johann P Ingimarsson; Ivan P Gorlov; John H Higgins; Elias S Hyams
Journal:  J Robot Surg       Date:  2016-06-04

8.  Nonchoriocarcinomatous Trophoblastic Tumors of the Testis: The Widening Spectrum of Trophoblastic Neoplasia.

Authors:  Muhammad T Idrees; Chia-Sui Kao; Jonathan I Epstein; Thomas M Ulbright
Journal:  Am J Surg Pathol       Date:  2015-11       Impact factor: 6.394

9.  Urinary incontinence and erectile dysfunction in patients with localized or locally advanced prostate cancer: A nationwide observational study.

Authors:  R W M Vernooij; R G H M Cremers; H Jansen; D M Somford; L A Kiemeney; G van Andel; B P Wijsman; M B Busstra; R J A van Moorselaar; E M Wijnen; F J Pos; M C C M Hulshof; P Hamberg; F van den Berkmortel; C A Hulsbergen-van de Kaa; G J L H van Leenders; J J Fütterer; I M van Oort; K K H Aben
Journal:  Urol Oncol       Date:  2020-07-15       Impact factor: 3.498

10.  Predictors of short-term and long-term incontinence after robot-assisted radical prostatectomy.

Authors:  I-Hung Shao; Ying-Hsu Chang; Chun-Ming Hou; Zheng-Feng Lin; Chun-Te Wu
Journal:  J Int Med Res       Date:  2017-07-18       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.